Development of a novel inducer for EBV lytic therapy

Area of Science:

• Virology
• Oncology
• Drug Discovery

Background:

• Epstein-Barr virus (EBV) infects over 90% of the global population, establishing latent infections in lymphoid and epithelial cells.
• EBV is associated with over 200,000 new cancer cases annually.
• Current treatments for EBV-positive cancers lack specificity and safety due to broad-spectrum cytotoxic drugs.

Purpose of the Study:

• To develop novel, targeted therapeutic strategies for EBV-associated malignancies.
• To identify small molecules capable of inducing the EBV lytic cycle, thereby potentially eliminating infected cells.

Main Methods:

• Development of high-throughput screening assays to identify EBV lytic cycle activators.
• Structure-activity relationship (SAR) studies of identified small molecules (C60 series).
• In vivo validation using EBV-positive gastric carcinoma mouse models (SNU719 and AGS-Akata).

Main Results:

• Identification of a novel class of small molecules, the C60 series, that efficiently activate the EBV lytic cycle.
• Demonstration of EBV reactivation in multiple cell lines, including lymphoblastoid and nasopharyngeal carcinoma.
• Successful reactivation of EBV in vivo in gastric carcinoma mouse models.

Conclusions:

• The C60 series represents a promising new class of compounds for targeting EBV-associated cancers.
• Targeting the EBV lytic cycle offers a potential strategy to overcome limitations of current chemotherapies.
• Further research into the C60 series could lead to more effective and selective treatments for EBV-driven malignancies.